

ONCrg Full Support™

COMPREHENSIVE MARKET INTELLIGENCE

ONCrg Full Support is an elite collection of interrelated competitive intelligence resources, produced by experts who are dedicated year-round to their study areas. These best-in-class, actionable resources include medical congress coverage, competitive landscapes, monthly surveillance, and ad hoc inquiry support in 31 cancer drug markets.

How We Support You

► ONCrg Conference™

Concise synopses of new data and their impact on competitive landscapes for knowledgeable insights from major congresses



Drug	Phase I	Phase II	Phase III	Pre-Reg	Approved	Current	Future
Trastuzumab	Completed	Completed	Completed	Completed	Completed	Completed	Completed
Herceptin	Completed	Completed	Completed	Completed	Completed	Completed	Completed
Ado-Trastuzumab	Completed	Completed	Completed	Completed	Completed	Completed	Completed
Trastuzumab emtansine	Completed	Completed	Completed	Completed	Completed	Completed	Completed
Trastuzumab deruxtecan	Completed	Completed	Completed	Completed	Completed	Completed	Completed
Trastuzumab emtansine	Completed	Completed	Completed	Completed	Completed	Completed	Completed
Trastuzumab emtansine	Completed	Completed	Completed	Completed	Completed	Completed	Completed
Trastuzumab emtansine	Completed	Completed	Completed	Completed	Completed	Completed	Completed
Trastuzumab emtansine	Completed	Completed	Completed	Completed	Completed	Completed	Completed
Trastuzumab emtansine	Completed	Completed	Completed	Completed	Completed	Completed	Completed

► ONCrg Pipeline Strategies™

Updated Quarterly

Detailed, cancer-specific analyses of treatment landscapes for drugs in Phase II development and beyond

► ONCrg Sentinel™

Updated Monthly

Comprehensive CI surveillance with shrewd discernment about relevant changes in each cancer market



► **ONCrg Advisory™ Ad Hoc** - Non-proprietary support within the scope of our medical conference, competitive landscape, and surveillance research

ONCrg COVERS

GI CANCERS

CRC
Esophageal
Gastric
HCC
PaC

GU CANCERS

Bladder
Prostate
RCC

LUNG

NSCLC
SCLC

BREAST/GYN

Breast
Cervical*
Endometrial
Ovarian

OTHERS

Gliomas
HNSCC
Melanoma
STS*

IMMUNO-ONCOLOGY

Emerging IO
Late Stage IO

HEME-ONC

ALL
AML
CLL
MDS
MM
MPNs
NHL

OTHER

PAN-TUMOR MOAs

ADCs
Cell Therapies
DDR*
Cancer Vaccines*

*Limited

MAJOR CONGRESSES

ASCO GI
ASCO GU
SGO
ELCC
AACR
ASCO
EHA
ICML
WCLC
ESMO
SITC
SNO
ASH
SABCS

Stacey Hood



Senior Director
stacey.hood@bp-rg.com

Brittany Daggett



Account Manager
brittany.daggett@onc-rg.com

Erica Wescott



Account Manager
erica.wescott@onc-rg.com

Kathryn Dahlke



Account Associate
kathryn.dahlke@onc-rg.com

Jillian James



Manager Client Services
jillian.james@onc-rg.com

Mike Reynolds



Co-Founder
michael.reynolds@onc-rg.com



ONCrg Competitive Intelligence

EXPERT, CONTENT-FOCUSED, BEST-IN-CLASS

Oncology Resource Group's deep understanding of clinical medicine, cumulative experience, and longevity are the foundation of our excellent service. Our talented analysts are dedicated to specific areas of study and work alongside each other to provide broad and unparalleled expertise and deliver the most accurate, insightful, and robust market-planning resources available.


Why We Make A Difference

► ONCrg Pipeline Strategies™

We deliver elite and cutting-edge reports built product by product, and placed into the context of the landscape by experts adept at evaluating scientific, clinical, and commercial content in their areas of specialization.

► ONCrg Sentinel™

We provide comprehensive, trustworthy, and easily digestible surveillance from skilled analysts who vigilantly monitor and constantly evaluate their dedicated study areas.



► ONCrg Conference™

We produce best-in-class congress intelligence with unparalleled insights due to our analysts' incisive, trial-by-trial understanding of cancer therapies, and their deep understanding of the development landscape.

► ONCrg Advisory™

We support clients with quick and reliable responses to ad hoc inquiries drawing from our team's deep understanding of cancer drug markets and their access to extensive and relevant in-house analytics.

“I've worked in pharma med affairs for over 20 years & also for an agency that specialized in R&D/pipeline updates and in all that time I've never seen reports that are anywhere near as good as yours in terms of content, presentation, relevance, thoroughness & timeliness. It's all superb work.”

See our website for more reviews www.onc-rg.com



Regina Cheung
Ph.D. in Immunology



Nikki Trunnell
Ph.D. in Cancer Biology



Lisa Komenda
Ph.D. in Molecular & Cell Biology



Sarah Lockhead
Ph.D. in Chemical & Systems Biology



Amanda Lanser
Ph.D. in Immunology



Carla Cabrera Johnson
Ph.D. in Tumor Biology



Patrick Nygren
Ph.D. in Pharmacology



Amanda Koch
Ph.D. in Biochemistry and Molecular Biology



Kristen Cordova
Ph.D. in Molecular Biology



Brooke Harrison
Ph.D. in Molecular Biology



Amber Mineo
Ph.D. in Cell & Development Biology



Stacey Aggarwal
Ph.D. in Pharmacology



Tina Shadpour,
PharmD, MS in Healthcare Decision Analysis



Robert Williams
Ph.D. in Biochemistry and Molecular Biology



Cara Lang
Ph.D. in Molecular Pathology and Immunology



Amanda Whitmill
Ph.D. in Biomedical Sciences



BioPharma Resource Groups



Solid Tumors, Hematologic, Immuno-Oncology, MOAs



CV & Metabolic

© Copyright 2025
BioPharma Resource Groups, LLC
All rights reserved. V051925

